Long-term follow-up of patients with a first clinical demyelinating event (clinically isolated syndrome) who received cladribine tablets in CLASSIC-MS: Findings for the ORACLE-MS cohort.

Autor: Giovannoni G; Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London, UK., Boyko A; Department of Neurology, Pirogov Russian National Research Medical University, Neurosurgery and Medical Genetics, Federal Center of Brain Research and Neurotechnologies, Moscow, Russia., Correale J; Department of Neurology, FLENI Institute, Buenos Aires, Argentina., Edan G; Department of Neurology, University Hospital of Rennes, Rennes, France., Freedman MS; Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada., Montalban X; Department of Neurology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain., Rammohan K; University of Miami School of Medicine, MS Research Center, Miami, FL, USA., Stefoski D; Department of Neurological Sciences, Rush University Medical Center, Chicago, IL, USA., Yamout B; Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE; American University of Beirut Medical Center, Beirut, Lebanon., Leist T; Division of Clinical Neuroimmunology, Jefferson University, Comprehensive MS Center, Philadelphia, PA, USA., Aydemir A; EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA., Borsi L; Merck Healthcare KGaA, Darmstadt, Germany., Verdun di Cantogno E; EMD Serono Research & Development Institute, Inc., an affiliate of Merck KGaA, Billerica, MA, USA.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2024 Dec 17, pp. 13524585241302170. Date of Electronic Publication: 2024 Dec 17.

A plain language summary on assessing the long-term effectiveness of cladribine tablets in people living with relapsing multiple sclerosis: The CLASSIC-MS study.

Autor: Giovannoni G; Blizard Institute, Barts & The London School of Medicine & Dentistry, Queen Mary University of London, London, UK., Boyko A; Pirogov Russian National Research Medical University, Department of Neurology, Neurosurgery & Medical Genetics, Federal Center of Brain Research & Neurotechnologies, Moscow, Russia., Correale J; Department of Neurology, FLENI Institute, Buenos Aires, Argentina., Edan G; Department of Neurology, University Hospital of Rennes, Rennes, France., Freedman MS; University of Ottawa, Department of Medicine & the Ottawa Hospital Research Institute, Ottawa, ON, Canada., Montalban X; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain., Rammohan K; University of Miami School of Medicine, MS Research Center, Miami, FL, USA., Stefoski D; Department of Neurological Sciences, Rush Medical College, Chicago, IL, USA., Yamout B; Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE.; American University of Beirut Medical Center, Beirut, Lebanon., Leist T; Division of Clinical Neuroimmunology, Jefferson University, Comprehensive MS Center, Philadelphia, PA, USA., Aydemir A; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA (an affiliate of Merck KGaA)., Borsi L; Merck Healthcare KGaA, Darmstadt, Germany., di Cantogno EV; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA (an affiliate of Merck KGaA).

Publikováno v: Neurodegenerative disease management [Neurodegener Dis Manag] 2023 Oct; Vol. 13 (5), pp. 261-268. Date of Electronic Publication: 2023 Aug 03.

Long-term follow-up of patients with relapsing multiple sclerosis from the CLARITY/CLARITY Extension cohort of CLASSIC-MS: An ambispective study.

Autor: Giovannoni G; Blizard Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK., Boyko A; Department of Neurology, Neurosurgery and Medical Genetics, Federal Center of Brain Research and Neurotechnologies, Pirogov Russian National Research Medical University, Moscow, Russia., Correale J; Department of Neurology, FLENI Institute, Buenos Aires, Argentina., Edan G; Department of Neurology, University Hospital of Rennes, Rennes, France., Freedman MS; Department of Medicine and the Ottawa Hospital Research Institute, University of Ottawa, Ottawa, ON, Canada., Montalban X; Department of Neurology-Neuroimmunology, Centre d'Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitario Vall d'Hebron, Barcelona, Spain., Rammohan K; MS Research Center, School of Medicine, University of Miami, Miami, FL, USA., Stefoski D; Department of Neurological Sciences, Rush Medical College, Chicago, IL, USA., Yamout B; Neurology Institute, Harley Street Medical Center, Abu Dhabi, UAE/American University of Beirut Medical Center, Beirut, Lebanon., Leist T; Division of Clinical Neuroimmunology, Comprehensive MS Center, Jefferson University, Philadelphia, PA, USA., Aydemir A; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA., Borsi L; Merck Healthcare KGaA, Darmstadt, Germany., Verdun di Cantogno E; EMD Serono Research & Development Institute, Inc., Billerica, MA, USA, an affiliate of Merck KGaA.

Publikováno v: Multiple sclerosis (Houndmills, Basingstoke, England) [Mult Scler] 2023 May; Vol. 29 (6), pp. 719-730. Date of Electronic Publication: 2023 Apr 03.

SMI-Capsular Fibrosis and Biofilm Dynamics: Molecular Mechanisms, Clinical Implications, and Antimicrobial Approaches.

Autor: Schoberleitner, Ines^1,2 (AUTHOR), Lackner, Michaela³ (AUTHOR), Coraça-Huber, Débora C.⁴ (AUTHOR), Augustin, Angela⁵ (AUTHOR), Imsirovic, Anja² (AUTHOR), Sigl, Stephan² (AUTHOR), Wolfram, Dolores² (AUTHOR) dolores.wolfram@i-med.ac.at

Publikováno v: International Journal of Molecular Sciences. Nov2024, Vol. 25 Issue 21, p11675. 32p.

Sind Bonusprogramme in der GKV ein erfolgreicher Anreiz zur Prävention? Eine ökonomische Analyse der zweiten Drei-Jahres Evaluation der Barmer GEK

Autor: Stock, S, Borsi, L, Schmidt, H, Möhlendick, K, Lüngen, M, Büscher, G

Publikováno v: Entscheiden trotz Unsicherheit; 14. Jahrestagung des Deutschen Netzwerks Evidenzbasierte Medizin; 20130315-20130316; Berlin; DOC13ebmP105 /20130311/

Hintergrund und Zielsetzung: Seit 2004 können die GKV nach § 65a SGB V für die regelmäßige Teilnahme an gesundheitsfördernden Maßnahmen, Mitgliedern einen Bonus gewähren. Bonus-Zahlungen müssen aus Einsparungen und Effizienzsteigerungen fina

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ca1d590657bb389af38869ed31ce67ed